Tagraxofusp
- Generic Name
- Tagraxofusp
- Brand Names
- Elzonris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2055491-00-2
- Unique Ingredient Identifier
- 8ZHS5657EH
- Background
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli. Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021.
- Indication
Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). In the US, it is approved for use in adults and pediatric patients over 2 years old. In Europe, it is only approved for use in adults.
- Associated Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Associated Therapies
- First-line Therapy
Menarini Group and MEDSIR Present the Phase III Study ADELA
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic
Fennec Pharmaceuticals Strengthens Executive Leadership
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.